Bausch + Lomb Reports the US Commercial Availability of Miebo (perfluorohexyloctane ophthalmic solution) for Dry Eye Disease
Shots:
- The company launched Miebo for the treatment of the signs and symptoms of dry eye disease. It is the first US FDA-approved treatment that directly targets tear evaporation, based on consistent results from two P-III trials (GOBI) and (MOJAVE) in 1217 patients
- The findings showed that Miebo met its primary clinical sign and patient-reported symptom EPs. These EPs included change from baseline at 8wk. in total corneal fluorescein staining (tCFS) and eye dryness Visual Analog Scale (VAS) score
- Patients reported relief from symptoms as early as day 15 and through day 57 with a reduction in VAS eye dryness score & a significant reduction in tCFS was also observed in both studies
Ref: Businesswire | Image: Bausch + Lomb
Related News:- Bausch + Lomb and Novaliq Receives the US FDA’s Approval of Miebo for Signs and Symptoms of Dry Eye Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
